Ileana Rodicio, MD
Allergy & Immunology · Miami, FLNPI 1689638629
Payments from drug & device makers
Across 1,117 payments — averaging $3359.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1.1M
- Novartis$821K
- GSK$726K
- Amphastar Pharmaceuticals, Inc.$436K
- Eli Lilly$272K
- AstraZeneca$207K
- plus $147K from 30 others
Across 2 payments — averaging $4526.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 212 | $1,143,267 |
| Novartis | 30 | $821,274 |
| GSK | 226 | $726,211 |
| Amphastar Pharmaceuticals, Inc. | 2 | $436,265 |
| Eli Lilly | 4 | $271,861 |
| AstraZeneca | 205 | $206,562 |
| Astrazeneca AB | 4 | $64,654 |
| Genentech, Inc. | 7 | $51,320 |
| Chiesi USA, Inc. | 4 | $15,468 |
| Sanofi | 80 | $5,866 |
| Regeneron Healthcare Solutions, Inc. | 67 | $2,216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $1,437 |
| Amgen(2 entities) | 51 | $1,087 |
| Genentech USA, Inc. | 30 | $810 |
| Optinose US, Inc. | 19 | $705 |
| Pharming Healthcare, Inc. | 18 | $550 |
| CSL Behring | 16 | $435 |
| Grifols USA, LLC | 22 | $428 |
| Pfizer | 12 | $245 |
| Galderma Laboratories, L.p. | 4 | $216 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $174 |
| Lilly USA, LLC | 5 | $167 |
| Biocryst US Sales Co., LLC | 7 | $165 |
| Boehringer Ingelheim | 8 | $159 |
| ADMA Biomanufacturing LLC | 2 | $149 |
| Shire North American Group Inc | 7 | $118 |
| Alk-abello, Inc | 6 | $113 |
| AbbVie | 3 | $74 |
| Octapharma USA, Inc. | 2 | $51 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Blueprint Medicines Corporation | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Kaleo, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $12 |
How this compares
$3,752,190 in reported general payments places this provider in the 95th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Miami
- Jose CarpioMiami$3.6M
- Nina RamirezMiami$833K
- Vicente ChavarriaMiami$828K
- Gary KleinerMiami$149K
- Neil GershmanMiami$18K
- Viviana SirvenMiami$14K
- Jaime LandmanAventura$3.9M
- Michael KohenDaytona Beach$3.6M
- Thomas CasaleTampa$1.7M
- Dennis LedfordTampa$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.